

BEST AVAILABLE COPY

WO 2005/002613

PCT/GB2004/002909

- 16 -

Claims

1. A pharmaceutical composition for the prevention or management of a condition caused by exposure to an 5 antithetical allele of a platelet by transfusion or during pregnancy by tolerisation, the composition comprising an immunologically effective platelet protein or peptide fragment thereof.

10 2. A pharmaceutical composition according to claim 1 wherein the condition is fetomaternal alloimmune response thrombocytopenia (FMAIT), post-transfusion purpura or platelet refractoriness.

15 3. A pharmaceutical composition according to either claim 1 or 2 wherein the platelet protein is a human platelet antigen (HPA).

4. A pharmaceutical composition according to claim 3 wherein 20 the HPA is selected from HPA-1a, HPA-1b, HPA-2a, HPA-2b, HPA-3a, HPA-3b, HPA-4a, HPA-4b, HPA-5a, HPA-5b, HPA-6a, HPA-6b, HPA-7a, HPA-7b, HPA-8a, HPA-8b, HPA-9a, HPA-9b, HPA-10a, HPA-10b, HPA-11a, HPA-11b.

25 5. A pharmaceutical composition according to claim 4 wherein the HPA has a genotype HPA-1a.

6. A pharmaceutical composition according to claim 5 wherein the HPA-1a has sequence SEQ ID No:1, 2, 3, 4, 5, 6 or 7.

30

7. A pharmaceutical composition according to any preceding claim wherein the composition is formulated for delivery through mucosal tissue.

- 17 -

8. A pharmaceutical composition substantially hereinbefore described with reference to Figure 1.

9. Use of an immunologically effective platelet protein or peptide fragment thereof in the manufacture for a medicament for the prevention or management of a condition by tolerisation caused by exposure to an antithetical allele of a platelet by transfusion or during pregnancy.

10 10. Use as substantially hereinbefore described with reference to Figure 1 in the manufacture for a medicament for the prevention or management of a condition by tolerisation caused by exposure to an antithetical allele of a platelet by transfusion or during pregnancy.